MiNK Therapeutics, Inc.

INKT

US6036931029

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 16:26:44 30/05/2024 BST			5-day change	1st Jan Change
0.96 ^USD	-0.91%		-1.10%	-8.95%

05-22	MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting	CI
05-14	Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024

Mink Therapeutics, Inc. Announces Appointment of Jennifer Buell as President

January 06, 2022 at 10:29 pm

MiNK Therapeutics, Inc. announced that effective December 31, 2021, Dr. Jennifer Buell resigned as Agenus Inc.'s, President and Chief Operating Officer to become the President of company.

Latest news about MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting	05-22	CI
Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
MiNK Therapeutics, Inc. announced that it has received $5.8 million in funding	05-13	CI
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures	05-13	MT
MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding	05-12	CI
Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024	03-21
MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-21	CI
MiNK Therapeutics, Inc. Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	03-06	CI
MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer	02-14	CI
MiNK Therapeutics, Inc. announced that it has received $5 million in funding from Agenus Inc.	02-11	CI
Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	02-06	CI
MiNK?s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	01-30	CI
Transcript : MiNK Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
MiNK Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
MiNK Therapeutics, Inc. Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023	11-03	CI
MiNK Therapeutics, Inc. Announces Resignation of as Director	17/10/23	CI
MiNK Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Index	23/06/23	CI
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Value Index	23/06/23	CI
MiNK Therapeutics Says Cell Product Candidate MiNK-215 Showed 'Potent Anti-Tumor Activity' in Preclinical Trial	18/05/23	MT
HC Wainwright Adjusts MiNK Therapeutics Price Target to $10 From $7, Maintains Buy Rating	12/05/23	MT
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Transcript : MiNK Therapeutics, Inc., Q1 2023 Earnings Call, May 11, 2023	11/05/23
Agenus Inc. spin-off 14.5% stake in MiNK Therapeutics, Inc. for $9.1 million.	30/04/23	CI

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Sector

Biotechnology & Medical Research

Calendar

12/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9688 USD

Average target price

8 USD

Spread / Average Target

+725.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MINK THERAPEUTICS, INC.	-8.95%	38.12M
MODERNA, INC.	+45.20%	56.69B
IQVIA HOLDINGS INC.	-2.88%	41B
LONZA GROUP AG	+38.22%	38.11B
CELLTRION, INC.	-11.22%	26.89B
ICON PUBLIC LIMITED COMPANY	+15.97%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.28%	18.59B
BIO-TECHNE CORPORATION	+0.01%	12.39B
MEDPACE HOLDINGS, INC.	+26.22%	11.99B
UNITED THERAPEUTICS CORPORATION	+22.79%	11.88B

Other Biotechnology & Medical Research